ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/HIF2a-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/HIF2a-inhibitor
6
trial(s) found.
NCT05536141
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors (
ARC-20
)
HIF2a inhibitor
Clear cell renal cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5037 - Glandore - Ashford Cancer Centre
NCT05468697
Advanced
Phase 1 / Phase 2
Recruiting
A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (
6482-024
)
CDK4/6 inhibitor
HIF2a inhibitor
Clear cell renal cell carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04924075
Advanced
Phase 2
Recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations (
6482-015
)
HIF2a inhibitor
Gastrointestinal stromal tumour
Pancreatic neuroendocrine tumour
Paraganglioma
Phaeochromocytoma
Solid tumour
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT04524871
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (
Morpheus-Liver
)
ADG126
Atezolizumab
Bevacizumab
HIF2a inhibitor
NKT2152
PPAR-alpha inhibitor
TPST-1120
Tiragolumab
Tobemstomig
Tocilizumab
anti-CTLA-4 monoclonal antibody
anti-IL-6 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,HIF2a-targeting
cancer therapy,IL-6-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PPAR-alpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ HIF2a inhibitor
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT02861573
Advanced
Phase 1 / Phase 2
Recruiting
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (
KEYNOTE-365
)
anti-PD-1 monoclonal antibody
+ HIF2a inhibitor
Castrate-resistant prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05239728
Curative
Phase 3
Active not recruiting
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-
6482-022
)
HIF2a inhibitor
anti-PD-1 monoclonal antibody
placebo
Clear cell renal cell carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (5)
Active not recruiting (1)
Recruitment Country and State
NSW (5)
VIC (4)
NZ (3)
SA (2)
WA (2)
QLD (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (3)
Phase 2 (1)
Phase 3 (1)
Trial Type
Advanced (5)
Curative (1)
Cancer Therapy Class
HIF2a
100%
PD-1
67%
PD-1/PD-L1
67%
TIGIT
33%
VEGF
33%
AXL
17%
KIT
17%
MET
17%
RET
17%
ROS1
17%
VEGFR
17%
VEGFR2
17%
CDK4
17%
CDK6
17%
CTLA4
17%
IL-6
17%
LAG3
17%
PD-L1
17%
PPAR-alpha
17%
AR
17%
CYP17A1
17%
PARP
17%
androgen axis
17%
Facility
2109 - North Ryde - Macquarie University Hospital (4)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
5037 - Glandore - Ashford Cancer Centre (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
6009 - Nedlands - One Clinical Research (1)
2031 - Randwick - Prince of Wales Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
Cancer Type
Cancer
Solid tumour
Urogenital cancer
Clear cell renal cell carcinoma
Kidney cancer
Gastrointestinal cancer
Upper gastrointestinal cancer
Adrenal cancer
Endocrine gland cancer
Gastro-entero-pancreatic neuroendocrine tumour
Gastrointestinal stromal tumour
Neuroendocrine tumour
Pancreatic cancer
Pancreatic neuroendocrine tumour
Pancreatobiliary cancer
Paraganglioma
Phaeochromocytoma
Hepatobiliary cancer
Hepatocellular carcinoma
Castrate-resistant prostate cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy